ATE364614T1 - Tumornekrose-faktor-gamma - Google Patents

Tumornekrose-faktor-gamma

Info

Publication number
ATE364614T1
ATE364614T1 AT95903521T AT95903521T ATE364614T1 AT E364614 T1 ATE364614 T1 AT E364614T1 AT 95903521 T AT95903521 T AT 95903521T AT 95903521 T AT95903521 T AT 95903521T AT E364614 T1 ATE364614 T1 AT E364614T1
Authority
AT
Austria
Prior art keywords
polypeptide
disclosed
gamma
tnf
necrosis factor
Prior art date
Application number
AT95903521T
Other languages
English (en)
Inventor
Guo-Liang Yu
Jian Ni
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE364614T1 publication Critical patent/ATE364614T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95903521T 1994-11-07 1994-11-07 Tumornekrose-faktor-gamma ATE364614T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/012880 WO1996014328A1 (en) 1994-11-07 1994-11-07 Tumor necrosis factor-gamma

Publications (1)

Publication Number Publication Date
ATE364614T1 true ATE364614T1 (de) 2007-07-15

Family

ID=22243251

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903521T ATE364614T1 (de) 1994-11-07 1994-11-07 Tumornekrose-faktor-gamma

Country Status (9)

Country Link
EP (1) EP0792278B1 (de)
JP (1) JP4046349B2 (de)
KR (1) KR100507431B1 (de)
AT (1) ATE364614T1 (de)
AU (1) AU708972B2 (de)
CA (1) CA2203655C (de)
DE (1) DE69434988T2 (de)
ES (1) ES2285701T3 (de)
WO (1) WO1996014328A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
AU731123B2 (en) * 1996-08-16 2001-03-22 Human Genome Sciences, Inc. Human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP0975754B2 (de) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin bindende proteine und deren rezeptoren
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
KR20010031713A (ko) 1997-11-03 2001-04-16 벤슨 로버트 에이치. 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
AU5124500A (en) * 1999-04-30 2000-11-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
WO2001010908A1 (en) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
AU783682B2 (en) * 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
EP1278544A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusionsproteine
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7498407B2 (en) 2001-11-09 2009-03-03 Georgetown University Vascular endothelial cell growth inhibitor, VEGI-192a
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2006521084A (ja) 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
KR101870056B1 (ko) 2008-09-26 2018-07-23 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
JP5867706B2 (ja) 2009-03-02 2016-02-24 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 増殖誘導リガンド（ａｐｒｉｌ）に対する抗体
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
EP2909324B1 (de) 2012-10-25 2020-02-26 Tocagen Inc. Retroviraler vektor mit mini-promoter-kassette
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
EP4105236A1 (de) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CN110121509B (zh) 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
US20210070871A1 (en) 2018-04-25 2021-03-11 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
CA2114311C (en) * 1991-11-25 1996-02-27 Richard Kian-Hock Wee Monoclonal wb b-cell line

Also Published As

Publication number Publication date
KR970707141A (ko) 1997-12-01
JPH10509030A (ja) 1998-09-08
KR100507431B1 (ko) 2005-12-21
JP4046349B2 (ja) 2008-02-13
AU1254795A (en) 1996-05-31
WO1996014328A1 (en) 1996-05-17
EP0792278A4 (de) 1999-09-22
DE69434988D1 (de) 2007-07-26
CA2203655A1 (en) 1996-05-17
CA2203655C (en) 2010-03-23
EP0792278B1 (de) 2007-06-13
ES2285701T3 (es) 2007-11-16
EP0792278A1 (de) 1997-09-03
AU708972B2 (en) 1999-08-19
DE69434988T2 (de) 2008-03-06

Similar Documents

Publication Publication Date Title
ATE364614T1 (de) Tumornekrose-faktor-gamma
EP0815202A4 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
ES2154354T3 (es) Ligandos tie-2, metodos para obtenerlos y sus usos.
CZ506785A3 (en) Human tumorous necrotic factor, process of its production, dna encoding the human tumorous necrotic factor, a cell transformed by this dna, agent in which the human tumorous necrotic factor is comprised and agent suitable to treating tumors
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
DE69930327D1 (de) Oxazolo-, Thiazolo- und Selenazolo-Ä4,5-cÜnaphthyridin-4-amine und Analoge davon
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE69737397D1 (de) Verwendung von mif-antagonisten zur krebstherapie
DE69334211D1 (de) Multidrug resistenz gen
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
DE3620656A1 (de) Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
PT914417E (pt) Dnase ii humana
MX9707617A (es) Factor de crecimiento de criptina humano.
ATE463566T1 (de) Tumor- und seneszenzsmarker
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
DK0409040T3 (da) Kolonistimulerende faktoraktivitetspromotorer
AU2947889A (en) Histamine release inhibitory factor and preparations therefore
EP0819168A4 (de) Menschlicher rezeptor für den tumor-nekrosis-faktor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties